Posted by Michael Wonder on 23 Jun 2026
Arrowhead Pharmaceuticals receives marketing authorisation in the European Union for Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome
22 June 2026 - Arrowhead Pharmaceuticals today announced that the European Commission has formally granted marketing authorization for Redemplo (plozasiran), a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome.
Redemplo is the first and only siRNA medicine authorized by the European Commission for adults with familial chylomicronemia syndrome, diagnosed either by the presence of clinical criteria or genetic testing.
